TY - JOUR

T1 - Liraglutide Reduces Cardiac Adipose Tissue in Type 2 Diabetes: A secondary analysis of the LIRAFLAME Randomized Placebo-Controlled Trial

AU - Rasmussen, Ida K. B.

AU - Zobel, Emilie H.

AU - Ripa, Rasmus S.

AU - Scholten, Bernt J. von

AU - Curovic, Viktor R.

AU - Jensen, Jacob K.

AU - Kjaer, Andreas

AU - Hansen, Tine W.

AU - Rossing, Peter

PY - 2021

Y1 - 2021

N2 - AimTo test the hypothesis that treatment with liraglutide can reduce cardiac adipose tissue.Materials and methodsLIRAFLAME is a randomized placebo-controlled, double-blind, parallel clinical study. Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/d or placebo for 26 weeks. Computed tomography was performed at baseline and at end of treatment to evaluate the cardiac adipose tissue volume, quantified automatically. We report the results of a secondary endpoint evaluating changes in cardiac adipose tissue.ResultsA total of 102 participants were randomly assigned to liraglutide (n = 51) or placebo (n = 51). At baseline, the mean (SD) cardiac adipose tissue volume was comparable between the liraglutide and the placebo group (232.6 [112.8] vs. 227.0 [103.2] mL; P = 0.80). The mean change in body weight was −3.7 (−4.8, −2.6) kg in the liraglutide and −0.18 (−0.76, 0.40) kg in the placebo group. From baseline to end of treatment the mean cardiac adipose tissue change was −11.5 (95% confidence interval −17.6, −5.4) mL in the liraglutide (P < 0.001) and −0.01 (−5.3, 5.3) mL in the placebo (P = 1.00) groups. The reduction in cardiac adipose tissue was significantly greater in the liraglutide compared to the placebo group (mean difference −11.4 [−19.4, −3.3] mL; P = 0.006), but significance was lost after adjustment for changes in body mass index (P = 0.46).ConclusionTreatment with liraglutide for 26 weeks was associated with a reduction in cardiac adipose tissue compared to placebo. The reduction was not independent of weight loss, suggesting that this is not a drug-specific effect.

AB - AimTo test the hypothesis that treatment with liraglutide can reduce cardiac adipose tissue.Materials and methodsLIRAFLAME is a randomized placebo-controlled, double-blind, parallel clinical study. Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/d or placebo for 26 weeks. Computed tomography was performed at baseline and at end of treatment to evaluate the cardiac adipose tissue volume, quantified automatically. We report the results of a secondary endpoint evaluating changes in cardiac adipose tissue.ResultsA total of 102 participants were randomly assigned to liraglutide (n = 51) or placebo (n = 51). At baseline, the mean (SD) cardiac adipose tissue volume was comparable between the liraglutide and the placebo group (232.6 [112.8] vs. 227.0 [103.2] mL; P = 0.80). The mean change in body weight was −3.7 (−4.8, −2.6) kg in the liraglutide and −0.18 (−0.76, 0.40) kg in the placebo group. From baseline to end of treatment the mean cardiac adipose tissue change was −11.5 (95% confidence interval −17.6, −5.4) mL in the liraglutide (P < 0.001) and −0.01 (−5.3, 5.3) mL in the placebo (P = 1.00) groups. The reduction in cardiac adipose tissue was significantly greater in the liraglutide compared to the placebo group (mean difference −11.4 [−19.4, −3.3] mL; P = 0.006), but significance was lost after adjustment for changes in body mass index (P = 0.46).ConclusionTreatment with liraglutide for 26 weeks was associated with a reduction in cardiac adipose tissue compared to placebo. The reduction was not independent of weight loss, suggesting that this is not a drug-specific effect.

U2 - 10.1111/dom.14516

DO - 10.1111/dom.14516

M3 - Journal article

C2 - 34387408

VL - 23

SP - 2651

EP - 2659

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 12

ER -